NeuroTherapia to Present Phase 2a Alzheimer's Disease Clinical Data at the AAIC 2026 Conference in London, UK

ConferencePositive

AI Analysis

Summary

NeuroTherapia will present Phase 2a clinical data from its Alzheimer's Disease program at the AAIC 2026 Conference in London on July 13th, demonstrating target engagement in a poster presentation.

Clinical Trial Data

Phase

Outcome Details

Phase 2a data demonstrating target engagement to be presented in poster format

Importance:5/10

Sentiment:

0.30

Alzheimer's Diseaseneurodegenerative diseasesoral therapiesPhase 2a dataAAIC 2026target engagement

Related Companies

$CBDY

Read the original article

Published by PR Newswire Biotech on July 13, 2026 10:00 AM

Read Original